Fenfluramine below the age of 2 years in Dravet syndrome: What about safety and efficacy?
Epilepsia · 2024
DOI: 10.1111/epi.17854 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2024. Verfasst von Nicola Pietrafusa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Neurology, Epilepsy, and Movement Disorders Unit, Full Member of European Reference Network EpiCARE, Bambino Gesù Children's Hospital, IRCCS, Rome, I…. Hauptthemen laut MEDLINE: Fenfluramine, Epilepsies, Myoclonic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Dravet syndrome (DS) is a rare developmental and epileptic encephalopathy. Infants with DS are especially vulnerable to the detrimental effects of prolonged and frequent seizures on development. Fenfluramine (FFA) is approved for the treatment of DS in patients aged 2 years and older. This study aims to evaluate the safety and efficacy of FFA in patients with DS younger than 2 years. We analyzed safety, tolerability, seizure, and neuropsychological outcome in a real‐world setting. Developmental profile was investigated using Griffiths Mental Development Scales (GMDS). Five patients received FFA at a mean age of 14.9 months (9.6–18.6). Median follow‐up was 13 months (interquartile range [IQR] = 12.9–24.4). All patients showed good tolerance to FFA. No significant variation of body mass index or echocardiographic issue was observed. Monthly median convulsive seizure frequency (MCSF) was 1.71 (IQR = 1.56–3.27) at the 6‐month baseline period and .92 (IQR = .43–1.28) at last follow‐up, with a median 54.43 (IQR = 40.91–60.83) percentage reduction in MCSF. Two of five patients had a performance improvement on GMDS subscales. Overall, the use of FFA below the age of 2 years in our small sample of patients was safe and represents a promising opportunity for seizure control and for protection of the neurodevelopmental outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology, Epilepsy, and Movement Disorders Unit, Full Member of European Reference Network EpiCARE, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Diagnosis and Treatment of Developmental Epilepsy, Child Neuropsychiatry Unit, Women and Children Department, AOU Sassari, Sassari, Italy.
- Neurology and Child Psychiatry Unit, Gaetano Barresi Department of Human Pathology of Adulthood and Development, University of Messina, Messina, Italy.
- Neurological Sciences and Rehabilitation Medicine Scientific Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
ORCID-Profile: Nicola Pietrafusa, Marina Trivisano, Susanna Casellato, Cinzia Correale, Simona Cappelletti, Paola De Liso, Ilaria Onida, Stefano Sotgiu, Ambra Butera, Nicola Specchio, Federico Vigevano
Zitieren
APA
Pietrafusa, N., Trivisano, M., Casellato, S., Correale, C., Cappelletti, S., De Liso, P., Onida, I., Sotgiu, S., Butera, A., Specchio, N., & Vigevano, F. (2024). Fenfluramine below the age of 2 years in Dravet syndrome: What about safety and efficacy?. Epilepsia. https://doi.org/10.1111/epi.17854
Vancouver
Pietrafusa N, Trivisano M, Casellato S, Correale C, Cappelletti S, De Liso P, et al. Fenfluramine below the age of 2 years in Dravet syndrome: What about safety and efficacy?. Epilepsia. 2024. doi:10.1111/epi.17854
BibTeX
@article{Pietrafusa2024,
author = {Pietrafusa, Nicola and Trivisano, Marina and Casellato, Susanna and Correale, Cinzia and Cappelletti, Simona and De Liso, Paola and Onida, Ilaria and Sotgiu, Stefano and Butera, Ambra and Specchio, Nicola and Vigevano, Federico},
title = {Fenfluramine below the age of 2 years in Dravet syndrome: What about safety and efficacy?},
journal = {Epilepsia},
year = {2024},
doi = {10.1111/epi.17854}
}
EUVIMED